Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Journal of Comparative Effectiveness Research|September 10, 2025
Composite endpoints in health technology assessment: Part 2 - expanding the evidence base with a framework for best modeling practiceAndrew Briggs, Jieling Chen, David Booth, et al.
Renal Failure|January 22, 2021
The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic reviewDanai Bem, Daniel Sugrue, Ben Wilding, et al.
Sensors (Basel, Switzerland)|April 13, 2023
Deep Metric Learning for Scalable Gait-Based Person Re-Identification Using Force Platform DataKayne A Duncanson, Simon Thwaites, David Booth, et al.
World Journal of Transplantation|September 30, 2016
Physical rehabilitation for lung transplant candidates and recipients: An evidence-informed clinical approachLisa Wickerson, Dmitry Rozenberg, Tania Janaudis-Ferreira, et al.
The Lancet. Infectious Diseases|February 24, 2015
Resistance to hepatitis C virus: potential genetic and immunological determinantsMichael M Mina, Fabio Luciani, Barbara Cameron, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|May 3, 2021
Exploring JSON-LD as an Executable Definition of FHIR RDF to EnableHarold R Solbrig, Harold R Solbrig, Eric Prud'hommeaux, et al.
Current Opinion in Cell Biology|July 8, 2014
Reliance of ER-mitochondrial calcium signaling on mitochondrial EF-hand Ca2+ binding proteins: Miros, MICUs, LETM1 and solute carriersGyörgy Hajnóczky, David Booth, György Csordás, et al.
Plos One|June 13, 2015
The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene FunctionJudith Field, Fernando Shahijanian, Stephen Schibeci, et al.
European Journal of Heart Failure|March 21, 2024
Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER dataJason A Davis, David Booth, Phil McEwan, et al.
European Journal of Heart Failure|June 22, 2023
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trialDavid Booth, Jason A Davis, Phil McEwan, et al.
Pageof 8